Melissa Moody
Psychiatry · Charleston, WVNPI 1750505384
Payments from drug & device makers
Across 1,460 payments — averaging $826.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$551K
- Otsuka America Pharmaceutical, Inc.$329K
- AbbVie$181K
- Axsome Therapeutics, Inc.$68K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$66K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$8K
- plus $3K from 30 others
What the payments were for
- Consulting fees$85,6297%
- Speaking & faculty fees$966,31980%
- Travel & lodging$129,10311%
- Food & beverage$25,2442%
- Education$1480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$544,986
- ABILIFY MAINTENA$183,429
- VRAYLAR$177,877
- REXULTI$142,696
- Auvelity$66,930
- CAPLYTA$64,940
- ABILIFY ASIMTUFII$44,445
How this compares
$1,206,443 in reported general payments places this provider in the 95th percentile of 177 psychiatry providers in West Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 32 | $253,947 |
| VraylarCariprazine Hcl | 80 | $144,571 |
| RexultiBrexpiprazole | 18 | $31,949 |
| VyvanseLisdexamfetamine Dimesylate | 11 | $4,295 |
| Buspirone Hcl | 85 | $1,872 |
| Clonazepam | 216 | $1,627 |
| Bupropion XlBupropion Hcl | 23 | $943 |
| Aripiprazole | 75 | $916 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 80 | $822 |
| Duloxetine Hcl | 99 | $787 |
| Quetiapine Fumarate | 85 | $756 |
| Alprazolam | 132 | $638 |
| Temazepam | 36 | $493 |
| Doxepin Hcl | 30 | $430 |
| Sertraline Hcl | 26 | $376 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $551,093 | $253,94732 claims |
| AbbVieVraylar | $180,939 | $144,57180 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $329,241 | $31,94918 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $117 | $4,29511 claims |
| Almatica Pharma LLCSertraline Hcl | $29 | $37626 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 177 psychiatry providers in West Virginia.
Other psychiatry in Charleston
- Fahd MousaCharleston$200K
- Lawrence KellyCharleston$41K
- Sidney LerfaldCharleston$14K
- Kiran DevarajCharleston$9K
- Krista RhodesCharleston$4K
- Veena BhanotCharleston$833
- Timothy ThistlethwaiteCharleston$773
- Nohl BraunCharleston$612
- April BaisdenScott Depot$775K
- Ryan WakimWheeling$772K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.